• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.1 no.1
• /
• pp.1-8
• /
• 2015

It is essential use of long term half life radioisotopes for positron emission tomography (PET) imaging study of biopharmaceuticals because most of biopharmaceuticals have long biological half-life. Some representative isotopes are $^{124}I$, $^{64}Cu$, $^{89}Zr$ and so on. These PET radioisotopes and their radiopharmaceuticals have recently received growing interest because of long half life and good imaging properties. Furthermore, $^{64}Cu$ and $^{89}Zr$ can be used in a number of radiopharmaceuticals due to its ease of conjugation to peptides and antibodies using the proper chelator. In recent years, since $^{124}I$ was first developed in 2005, we have been studied to develop an efficient method and procedure for producing these radioisotopes, and we have made considerable progress in production of long term half life radioisotopes. This review introduces the general production system, purification procedure, and several advances on targeting method for $^{124}I$ and $^{64}Cu$ in KIRAMS.

• Journal of Radiation Industry
• /
• v.8 no.2
• /
• pp.77-81
• /
• 2014

Hyaluronic acid is a disaccharide polymer that consists of glucuronic acid and N-acetylglucosamine, and is a glycosaminoglycan. It is widely distributed in animal connective tissue, coexisting with chondroitin sulfate. It forms viscous secretions or gel by bonding to protein in the body, and thus maintains and lubricates tissue structures. In addition, its antibiotic properties are applied to cosmetics and pharmaceuticals. Therefore, it has recently been an object of great interest at cosmetic and pharmaceutical companies. $^{125}I$ has a longer half-life (59.4 days) than many other radioisotopes, and is therefore useful to long-term studies. In this study, a facile and efficient procedure for the synthesis of $^{125}I$-labeled hyaluronic acid has been designed for in vivo imaging and pharmacokinetic studies of hyaluronic acid, which are required for the development of new drugs.